(Q43292779)

18 November 2017

Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

18 November 2017

1 reference

1 reference

1 reference

1

1 reference

18 November 2017

Sumant Khanna

2

1 reference

18 November 2017

Koushik Chakrabarty

3

1 reference

18 November 2017

Anita Mahadevan

4

1 reference

18 November 2017

Rita Christopher

5

1 reference

18 November 2017

S K Shankar

6

1 reference

18 November 2017

language of work or name

English

0 references

publication date

12 August 2009

1 reference

18 November 2017

Neuropsychopharmacology

1 reference

18 November 2017

34

1 reference

18 November 2017

2489-2496

1 reference

18 November 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2009.77

18 November 2017

0 references

cites work

Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Glutamatergic dysfunction in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Incidence of anti-brain antibodies in children with obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Neuroimaging studies of obsessive-compulsive disorder in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Low cerebrospinal fluid glutamate and glycine in refractory affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

The Yale-Brown Obsessive Compulsive Scale. II. Validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Tic disorders and obsessive-compulsive disorder: is autoimmunity involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Antibody-mediated neuronal cell signaling in behavior and movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Brain imaging in pediatric obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Antineuronal antibodies in a group of children with obsessive-compulsive disorder and Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Anti-brain antibodies in PANDAS versus uncomplicated streptococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Determination of in vivo amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Antibodies against human putamen in children with Tourette syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Association Testing of the Positional and Functional Candidate Gene SLC1A1/EAAC1 in Early-Onset Obsessive-compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Glycine potentiates the NMDA response in cultured mouse brain neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

inferred from DOI database lookup

7 January 2021

based on heuristic

The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

inferred from DOI database lookup

7 January 2021

based on heuristic

Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2009.77

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NPP.2009.77

1 reference

Dimensions Publication ID

18 November 2017

0 references

1 reference